JW Pharmaceutical Corp (001067) - Cash Flow Conversion Efficiency
Based on the latest financial reports, JW Pharmaceutical Corp (001067) has a cash flow conversion efficiency ratio of 0.132x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩46.92 Billion ≈ $31.79 Million USD) by net assets (₩354.10 Billion ≈ $239.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
JW Pharmaceutical Corp - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how JW Pharmaceutical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read JW Pharmaceutical Corp debt and liabilities for a breakdown of total debt and financial obligations.
JW Pharmaceutical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of JW Pharmaceutical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nelson Resources Ltd
AU:NES
|
-0.099x |
|
Openlearning Ltd
AU:OLL
|
0.356x |
|
Cell Impact AB
ST:CI
|
-0.104x |
|
KWESST MICRO SYS.INC.
F:62UA
|
N/A |
|
AHT Syngas Technology NV
F:3SQ1
|
0.008x |
|
Bergenbio ASA
OL:BGBIO
|
-2.287x |
|
PLENUM AG NA O.N.
F:PLEK
|
N/A |
|
PLAYWITH Inc
KQ:023770
|
0.105x |
Annual Cash Flow Conversion Efficiency for JW Pharmaceutical Corp (2014–2024)
The table below shows the annual cash flow conversion efficiency of JW Pharmaceutical Corp from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 001067 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩329.49 Billion ≈ $223.29 Million |
₩79.39 Billion ≈ $53.80 Million |
0.241x | -26.62% |
| 2023-12-31 | ₩265.44 Billion ≈ $179.89 Million |
₩87.16 Billion ≈ $59.07 Million |
0.328x | +30.59% |
| 2022-12-31 | ₩225.76 Billion ≈ $152.99 Million |
₩56.76 Billion ≈ $38.47 Million |
0.251x | +161.57% |
| 2021-12-31 | ₩188.54 Billion ≈ $127.77 Million |
₩18.12 Billion ≈ $12.28 Million |
0.096x | -68.37% |
| 2020-12-31 | ₩207.47 Billion ≈ $140.60 Million |
₩63.05 Billion ≈ $42.73 Million |
0.304x | +25.93% |
| 2019-12-31 | ₩230.09 Billion ≈ $155.93 Million |
₩55.53 Billion ≈ $37.63 Million |
0.241x | +20.47% |
| 2018-12-31 | ₩260.11 Billion ≈ $176.27 Million |
₩52.11 Billion ≈ $35.31 Million |
0.200x | +62.17% |
| 2017-12-31 | ₩270.78 Billion ≈ $183.50 Million |
₩33.45 Billion ≈ $22.67 Million |
0.124x | +406.54% |
| 2016-12-31 | ₩276.31 Billion ≈ $187.25 Million |
₩6.74 Billion ≈ $4.57 Million |
0.024x | +231.67% |
| 2015-12-31 | ₩225.41 Billion ≈ $152.75 Million |
₩-4.17 Billion ≈ $-2.83 Million |
-0.019x | -155.99% |
| 2014-12-31 | ₩220.02 Billion ≈ $149.11 Million |
₩7.28 Billion ≈ $4.93 Million |
0.033x | -- |
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more